Development of organometallic (organo‐transition metal) pharmaceuticals
Identifieur interne : 001E81 ( Main/Exploration ); précédent : 001E80; suivant : 001E82Development of organometallic (organo‐transition metal) pharmaceuticals
Auteurs : Claire S. Allardyce [Suisse] ; Antoine Dorcier [Suisse] ; Claudine Scolaro [Suisse] ; Paul J. Dyson [Suisse]Source :
- Applied Organometallic Chemistry [ 0268-2605 ] ; 2005-01.
English descriptors
- Teeft :
- Allardyce, Ammonia ligands, Anticancer, Anticancer activity, Anticancer compounds, Anticancer drug, Anticancer properties, Appl, Biological activity, Biological systems, Biological target, Bioorganometallic, Bioorganometallic chemistry, Blood vessels, Cancer activity, Cancer cells, Cancer chemother, Cell division, Chem, Cisplatin, Clinical trials, Commun, Compound, Compound disease, Copyright, Covalent interactions, Cyclopentadienyl rings, Diseased tissues, Drug activity, Drug targets, Dyson, General toxicity, Healthy cells, Healthy tissues, Higher solubility, Hydrogen bond, Hypoxic tumour cells, Inorg, Jaouen, John wiley sons, Lewis lung carcinoma, Ligand, Ligand exchange, Metal complexes, Molecular mechanism, Normal cells, Oestrogendependent cancers antiproliferative activity, Organometal, Organometallic, Organometallic chemistry, Organometallic compounds, Organometallic groups, Organometallic pharmaceuticals, Organometallics, Osmium analogues, Parrondo iglesias, Pharmaceutical, Physiological conditions, Platinum compounds, Proteomics methods, Reinoculated tumours, Ruthenium, Ruthenium compounds, Ruthenium coordination complexes, Science foundation, Serum transferrin, Tissue culture, Titanocene dichloride, Transferrin, Transferrin receptors, Tumour, Xvth fechem conference.
Abstract
This paper is aimed at introducing the organometallic chemist to the fascinating area of organometallic pharmaceuticals. It commences by identifying the properties of organometallic (transition metal) compounds that lend themselves to medical applications. Next, the specialized techniques and methods that are used to assess the medicinal properties of compounds are summarized, and although these techniques are not restricted to organometallic compounds, all examples are concerned with organometallic compounds. The design and evaluation of organometallic compounds for medicinal applications are described in context with the diseases they have been evaluated against, and areas are identified that may have most potential for organometallic pharmaceuticals. Some new results, including the first example of an organo‐osmium compound that might exhibit effective anticancer properties, are also described. Copyright © 2005 John Wiley & Sons, Ltd.
The medicinal properties of organometallic compounds are under intensive evaluation, especially in the treatment of cancer, as they exhibit certain properties that appear to be superior to those of other types of drug. We identify these properties and show where current organometallic drugs are finding most interest, and describe some recent results from our own research.
Url:
DOI: 10.1002/aoc.725
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002384
- to stream Istex, to step Curation: 002384
- to stream Istex, to step Checkpoint: 000D31
- to stream Main, to step Merge: 001E95
- to stream Main, to step Curation: 001E81
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of organometallic (organo‐transition metal) pharmaceuticals</title><author><name sortKey="Allardyce, Claire S" sort="Allardyce, Claire S" uniqKey="Allardyce C" first="Claire S." last="Allardyce">Claire S. Allardyce</name></author><author><name sortKey="Dorcier, Antoine" sort="Dorcier, Antoine" uniqKey="Dorcier A" first="Antoine" last="Dorcier">Antoine Dorcier</name></author><author><name sortKey="Scolaro, Claudine" sort="Scolaro, Claudine" uniqKey="Scolaro C" first="Claudine" last="Scolaro">Claudine Scolaro</name></author><author><name sortKey="Dyson, Paul J" sort="Dyson, Paul J" uniqKey="Dyson P" first="Paul J." last="Dyson">Paul J. Dyson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C1C8D28204E0C16EBBE21152880CF0F7AE4E5CC4</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/aoc.725</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-HN6ZHLLJ-X/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002384</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002384</idno><idno type="wicri:Area/Istex/Curation">002384</idno><idno type="wicri:Area/Istex/Checkpoint">000D31</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D31</idno><idno type="wicri:doubleKey">0268-2605:2005:Allardyce C:development:of:organometallic</idno><idno type="wicri:Area/Main/Merge">001E95</idno><idno type="wicri:Area/Main/Curation">001E81</idno><idno type="wicri:Area/Main/Exploration">001E81</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Development of organometallic (organo‐transition metal) pharmaceuticals</title><author><name sortKey="Allardyce, Claire S" sort="Allardyce, Claire S" uniqKey="Allardyce C" first="Claire S." last="Allardyce">Claire S. Allardyce</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne, EPFL‐BCH, CH‐1015 Lausanne</wicri:regionArea><wicri:noRegion>CH‐1015 Lausanne</wicri:noRegion></affiliation></author><author><name sortKey="Dorcier, Antoine" sort="Dorcier, Antoine" uniqKey="Dorcier A" first="Antoine" last="Dorcier">Antoine Dorcier</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne, EPFL‐BCH, CH‐1015 Lausanne</wicri:regionArea><wicri:noRegion>CH‐1015 Lausanne</wicri:noRegion></affiliation></author><author><name sortKey="Scolaro, Claudine" sort="Scolaro, Claudine" uniqKey="Scolaro C" first="Claudine" last="Scolaro">Claudine Scolaro</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne, EPFL‐BCH, CH‐1015 Lausanne</wicri:regionArea><wicri:noRegion>CH‐1015 Lausanne</wicri:noRegion></affiliation></author><author><name sortKey="Dyson, Paul J" sort="Dyson, Paul J" uniqKey="Dyson P" first="Paul J." last="Dyson">Paul J. Dyson</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne, EPFL‐BCH, CH‐1015 Lausanne</wicri:regionArea><wicri:noRegion>CH‐1015 Lausanne</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Suisse</country></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Correspondence address: Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne, EPFL‐BCH, CH‐1015 Lausanne</wicri:regionArea><wicri:noRegion>CH‐1015 Lausanne</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Applied Organometallic Chemistry</title><title level="j" type="alt">APPLIED ORGANOMETALLIC CHEMISTRY</title><idno type="ISSN">0268-2605</idno><idno type="eISSN">1099-0739</idno><imprint><biblScope unit="vol">19</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="10">10</biblScope><biblScope unit="page-count">10</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2005-01">2005-01</date></imprint><idno type="ISSN">0268-2605</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0268-2605</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Allardyce</term><term>Ammonia ligands</term><term>Anticancer</term><term>Anticancer activity</term><term>Anticancer compounds</term><term>Anticancer drug</term><term>Anticancer properties</term><term>Appl</term><term>Biological activity</term><term>Biological systems</term><term>Biological target</term><term>Bioorganometallic</term><term>Bioorganometallic chemistry</term><term>Blood vessels</term><term>Cancer activity</term><term>Cancer cells</term><term>Cancer chemother</term><term>Cell division</term><term>Chem</term><term>Cisplatin</term><term>Clinical trials</term><term>Commun</term><term>Compound</term><term>Compound disease</term><term>Copyright</term><term>Covalent interactions</term><term>Cyclopentadienyl rings</term><term>Diseased tissues</term><term>Drug activity</term><term>Drug targets</term><term>Dyson</term><term>General toxicity</term><term>Healthy cells</term><term>Healthy tissues</term><term>Higher solubility</term><term>Hydrogen bond</term><term>Hypoxic tumour cells</term><term>Inorg</term><term>Jaouen</term><term>John wiley sons</term><term>Lewis lung carcinoma</term><term>Ligand</term><term>Ligand exchange</term><term>Metal complexes</term><term>Molecular mechanism</term><term>Normal cells</term><term>Oestrogendependent cancers antiproliferative activity</term><term>Organometal</term><term>Organometallic</term><term>Organometallic chemistry</term><term>Organometallic compounds</term><term>Organometallic groups</term><term>Organometallic pharmaceuticals</term><term>Organometallics</term><term>Osmium analogues</term><term>Parrondo iglesias</term><term>Pharmaceutical</term><term>Physiological conditions</term><term>Platinum compounds</term><term>Proteomics methods</term><term>Reinoculated tumours</term><term>Ruthenium</term><term>Ruthenium compounds</term><term>Ruthenium coordination complexes</term><term>Science foundation</term><term>Serum transferrin</term><term>Tissue culture</term><term>Titanocene dichloride</term><term>Transferrin</term><term>Transferrin receptors</term><term>Tumour</term><term>Xvth fechem conference</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This paper is aimed at introducing the organometallic chemist to the fascinating area of organometallic pharmaceuticals. It commences by identifying the properties of organometallic (transition metal) compounds that lend themselves to medical applications. Next, the specialized techniques and methods that are used to assess the medicinal properties of compounds are summarized, and although these techniques are not restricted to organometallic compounds, all examples are concerned with organometallic compounds. The design and evaluation of organometallic compounds for medicinal applications are described in context with the diseases they have been evaluated against, and areas are identified that may have most potential for organometallic pharmaceuticals. Some new results, including the first example of an organo‐osmium compound that might exhibit effective anticancer properties, are also described. Copyright © 2005 John Wiley & Sons, Ltd.</div><div type="abstract" xml:lang="en">The medicinal properties of organometallic compounds are under intensive evaluation, especially in the treatment of cancer, as they exhibit certain properties that appear to be superior to those of other types of drug. We identify these properties and show where current organometallic drugs are finding most interest, and describe some recent results from our own research.</div></front></TEI><affiliations><list><country><li>Suisse</li></country></list><tree><country name="Suisse"><noRegion><name sortKey="Allardyce, Claire S" sort="Allardyce, Claire S" uniqKey="Allardyce C" first="Claire S." last="Allardyce">Claire S. Allardyce</name></noRegion><name sortKey="Dorcier, Antoine" sort="Dorcier, Antoine" uniqKey="Dorcier A" first="Antoine" last="Dorcier">Antoine Dorcier</name><name sortKey="Dyson, Paul J" sort="Dyson, Paul J" uniqKey="Dyson P" first="Paul J." last="Dyson">Paul J. Dyson</name><name sortKey="Dyson, Paul J" sort="Dyson, Paul J" uniqKey="Dyson P" first="Paul J." last="Dyson">Paul J. Dyson</name><name sortKey="Dyson, Paul J" sort="Dyson, Paul J" uniqKey="Dyson P" first="Paul J." last="Dyson">Paul J. Dyson</name><name sortKey="Scolaro, Claudine" sort="Scolaro, Claudine" uniqKey="Scolaro C" first="Claudine" last="Scolaro">Claudine Scolaro</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E81 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E81 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C1C8D28204E0C16EBBE21152880CF0F7AE4E5CC4
|texte= Development of organometallic (organo‐transition metal) pharmaceuticals
}}
| This area was generated with Dilib version V0.6.33. |  |